½ÃÀ庸°í¼­
»óǰÄÚµå
1358160

³ª³ë¹Ùµð ½ÃÀå : Á¦Ç° À¯Çüº°, Ä¡·á ¿µ¿ªº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°

Nanobodies Market, By Product Type, By Therapeutic Area, By Application, By End User, By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ³ª³ë¹Ùµð ½ÃÀåÀº 2023³â¿¡´Â 3¾ï 6,860¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤¡¤¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£ Áß(2023-2030³â) CAGRÀº 24.1%¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸®Æ÷Æ® ´ë»ó ¹üÀ§ ¸®Æ÷Æ® »ó¼¼
±âÁسâ 2022³â 2023³â ½ÃÀå ±Ô¸ð 3¾ï 6,860¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2018-2021³â ¿¹Ãø ±â°£ 2023-2030
¿¹Ãø ±â°£ CAGR 24.10% 2030³â ½ÃÀå ±Ô¸ð ¿¹Ãø 16¾ï 7,190¸¸ ´Þ·¯
¼¼°èÀÇ ³ª³ë¹Ùµð ½ÃÀå Á¡À¯À²(%), Á¦Ç° À¯Çüº°, 2023³â
Nanobodies Market-IMG1

"³ª³ë ¹Ùµð"·Î ¾Ë·ÁÁø ´ÜÀÏ µµ¸ÞÀÎ Ç×ü´Â Æ÷À¯·ù Áß¼â Ç×ü¿¡¼­ ÆÄ»ýµÈ °ÍÀ¸·Î, ³ª³ë Å©±âÀÇ Å©±â, °ß°íÇÑ ±¸Á¶, ¼ö¿ë¾×¿¡¼­ ¾ÈÁ¤ÀûÀÎ ¿ëÇØ¼º °Åµ¿, °¡¿ªÀû ´Ü¹éÁú Á¢Èû, ÇϳªÀÇ µ¿Á· Ç¥Àû¿¡ ´ëÇÑ ³ôÀº Ä£¹Ðµµ¿Í ƯÀ̼º µî Ưº°ÇÑ Æ¯Â¡À» °¡Áö°í ÀÖ½À´Ï´Ù. ³ª³ëü´Â ±âÃʰúÇп¡¼­ ÀÓ»ó Ä¡·á±îÁö ´Ù¾çÇÑ ÀÀ¿ëÀÌ °¡´ÉÇÕ´Ï´Ù. ³ª³ëü´Â Å©±â°¡ ÀÛ°í ´ÜÀÏ µµ¸ÞÀÎ »ç½½À̱⠶§¹®¿¡ °áÇÕ Ç¥¸éÀÌ Å©°í ºñƯÀÌÀû ¹è°æ °áÇÕÀÌ ³·¾Æ ģȭ·Â Æ÷ȹ ½Ã¾àÀ¸·Î »ç¿ëµË´Ï´Ù. ¶ÇÇÑ ³ª³ëü´Â Ç× Æù ºô·¹ºê¶õÆ® ÀÎÀÚ(anti-Von Willebrand factor)¸¦ ±æÇ×ÇÏ¿© Ç÷ÀüÁõÀ» ¿¹¹æÇϰí, Ç× TNF-¥á¸¦ ¾ïÁ¦ÇÏ¿© °üÀý¿°À» Ä¡·áÇÏ´Â µî ¸®°£µå¿Í ¼ö¿ëüÀÇ »óÈ£ ÀÛ¿ëÀ» ¾ïÁ¦ÇÏ¿© ¾Ï ¹× ±âŸ Áúº´À» Ä¡·áÇÏ´Â µ¥ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ³ª³ëü´Â ¼¼Æ÷ ³»¿¡¼­ ¹ßÇö½Ã۰í Çü±¤ ´Ü¹éÁú°ú À¶ÇÕÇÏ¿© Ç׿ø Ȱ¼ºÀ» ¸ð´ÏÅ͸µÇÒ ¼öµµ ÀÖ½À´Ï´Ù. ³ª³ëü´Â ´Ü¹éÁúÀÇ ¾ÈÁ¤È­Á¦·Î¼­ ÀûÇÕÇϸç, ÀÌ´Â ´Ü¹éÁúÀÇ °áÁ¤È­¿¡¼­ ƯÈ÷ Áß¿äÇÕ´Ï´Ù. µû¶ó¼­ ³ª³ëü´Â ´Ü¹éÁúÀ» ƯÁ¤ ÇüÅ·Π°íÁ¤Çϰí À¯¿¬ÇÑ µµ¸ÞÀÎÀ» ¾ÈÁ¤È­½Ãų ¼ö ÀÖÀ¸¹Ç·Î ¸¹Àº ´Ü¹éÁú °áÁ¤È­ ¿¬±¸¿¡ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÌÀ¯·Î ³ª³ë ¹ÙµðÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÏ¿© ³ª³ë ¹Ùµð ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

³ª³ë ¹Ùµð ½ÃÀåÀÇ ÁÖ¿ä ¾÷üµéÀº Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ °­È­Çϱâ À§ÇØ ¿¬±¸°³¹ß¿¡ ÅõÀÚÇÏ°í ½ÅÁ¦Ç° °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. µû¶ó¼­ ÀÌ·¯ÇÑ Ã·´Ü Á¦Ç° ½ÃÀå µµÀÔÀº ¿¹Ãø ±â°£ Áß ¼¼°è ³ª³ë ¹Ùµð ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î 2020³â 10¿ù ¼¼°è °úÇбâ¼ú ±â¾÷ÀÎ ¸ÓÅ©(Merck KGaA)´Â ¼¼°è ÇコÄÉ¾î ±â¾÷ÀÎ ³ë¹ÙƼ½º(Novartis AG)¿Í °ñ°üÀý¿°(OA) Ä¡·á °¡´É¼ºÀÌ ÀÖ´Â Ç× ADAMTS5 ³ª³ëü M6495ÀÇ °³¹ß¿¡ ´ëÇÑ ¶óÀ̼±½º °è¾àÀ» ü°áÇÏ¿´½À´Ï´Ù. À̸¦ ÅëÇØ °ñ°üÀý¿° ȯÀÚµéÀÇ Ä¡·á ¿É¼ÇÀÌ ´Ã¾î³¯ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • ¼¼°èÀÇ ³ª³ë¹Ùµð ½ÃÀåÀ» »ó¼¼ ºÐ¼®Çϰí, 2022³âÀ» ±âÁسâÀ¸·Î ÇÑ ¿¹Ãø ±â°£(2023-2030³â)ÀÇ ½ÃÀå ±Ô¸ð ¹× ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» Á¦°øÇϰí ÀÖ½À´Ï´Ù.
  • ¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®ÀÇ ÀáÀçÀû ¸ÅÃâ ±âȸ¸¦ ¼³¸íÇϰí, ½ÃÀå¿¡ ´ëÇÑ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¿¡ ´ëÇØ ÇØ¼³Çϰí ÀÖ½À´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤ÅÃÇÏ´Â °æÀï Àü·« µî¿¡ °üÇÑ ÁÖ¿ä ÀλçÀÌÆ®µµ Á¦°øÇϰí ÀÖ½À´Ï´Ù.
  • ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ½ÇÀû, Àü·« µîÀÇ ÆÄ¶ó¹ÌÅÍ¿¡ ±â¹ÝÇÏ¿© ¼¼°èÀÇ ³ª³ë¹Ùµð ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ÇÁ·ÎÆÄÀϸµÇϰí ÀÖ½À´Ï´Ù.
  • ÀÌ ¸®Æ÷Æ®·ÎºÎÅÍÀÇ ÀλçÀÌÆ®¿¡ ÀÇÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ ¹× ±â¾÷ÀÇ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° ¹ß¸Å, À¯Çü ¾÷±×·¹À̵å, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ °üÇÑ Á¤º¸¿¡ ±â¹ÝÇÑ ÀÇ»ç°áÁ¤À» ½ÃÇàÇÒ ¼ö ÀÖ½À´Ï´Ù.
  • ¼¼°èÀÇ ³ª³ë¹Ùµð ½ÃÀå ¸®Æ÷Æ®´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü¿©¾÷ü, À繫 ¾Ö³Î¸®½ºÆ® µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¿¡°Ô ´ëÀÀÇϰí ÀÖ½À´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚ´Â ¼¼°èÀÇ ³ª³ë¹Ùµð ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦

  • Á¶»çÀÇ ¸ñÀû
  • °¡Á¤
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • ¸®Æ÷Æ® ¼³¸í
    • ½ÃÀåÀÇ Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
  • ÃËÁø¿äÀÎ
  • ¾ïÁ¦¿äÀÎ
  • ±âȸ
    • ÃÖ±Ù µ¿Çâ
    • ÇÕº´, Àμö ¹× Çù¾÷
    • ±ÔÁ¦ ½Ã³ª¸®¿À
    • ÁÖ¿ä ¹ßÀü
    • PEST ºÐ¼®
    • PorterÀÇ »ê¾÷ ºÐ¼®

Á¦4Àå ¼¼°èÀÇ ³ª³ë¹Ùµð ½ÃÀå, COVID-19ÀÇ ¿µÇ⠺м®

    • °æÁ¦Àû ¿µÇâ
    • ½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½º(COVID-19) ¿ªÇÐ
    • ¼ö¿ä¿Í °ø±Þ¿¡ ´ëÇÑ ¿µÇâ

Á¦5Àå ¼¼°èÀÇ ³ª³ë¹Ùµð ½ÃÀå, Á¦Ç° À¯Çüº°, 2018-2030³â

  • Àϰ¡ ³ª³ë¹Ùµð
  • 2°¡ ³ª³ë¹Ùµð
  • ÀÌÁ߯¯À̼º ³ª³ë¹Ùµð
  • ¹ÙÀÌÆÄ¶óÅäÇÈ ³ª³ë¹Ùµð
  • ´Ù°¡ ³ª³ë¹Ùµð
  • À¶ÇÕ ³ª³ë¹Ùµð

Á¦6Àå ¼¼°èÀÇ ³ª³ë¹Ùµð ½ÃÀå, Ä¡·á ¿µ¿ªº°, 2018-2030³â

  • Á¾¾çÇÐ
  • °¨¿°Áõ
  • ¿°Áõ¼º Áúȯ ¹× ÀÚ°¡¸é¿ªÁúȯ
  • ½Å°æÇÐÀû Àå¾Ö
  • ±âŸ

Á¦7Àå ¼¼°èÀÇ ³ª³ë¹Ùµð ½ÃÀå, ¿ëµµº°, 2018-2030³â

  • Ä¡·á¿ë
  • Áø´Ü
  • Á¶»ç

Á¦8Àå ¼¼°èÀÇ ³ª³ë¹Ùµð ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº°, 2018-2030³â

  • º´¿ø
  • ¹ÙÀÌ¿ÀÀǾàǰ ±â¾÷
  • Áø´Ü ¿¬±¸¼Ò
  • ±âŸ

Á¦9Àå ¼¼°èÀÇ ³ª³ë¹Ùµð ½ÃÀå, Áö¿ªº°, 2018-2030³â

  • ºÏ¹Ì
  • ¹Ì±¹
  • ij³ª´Ù
  • À¯·´
  • ¿µ±¹
  • µ¶ÀÏ
  • ÀÌÅ»¸®¾Æ
  • ÇÁ¶û½º
  • ½ºÆäÀÎ
  • ·¯½Ã¾Æ
  • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áß±¹
  • Àεµ
  • ÀϺ»
  • ASEAN
  • È£ÁÖ
  • Çѱ¹
  • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • ºê¶óÁú
  • ¸ß½ÃÄÚ
  • ¾Æ¸£ÇîÆ¼³ª
  • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿
  • GCC
  • À̽º¶ó¿¤
  • ±âŸ Áßµ¿
  • ¾ÆÇÁ¸®Ä«
  • ºÏ¾ÆÇÁ¸®Ä«
  • Áß¾Ó¾ÆÇÁ¸®Ä«
  • ³²¾ÆÇÁ¸®Ä«

Á¦10Àå °æÀï ±¸µµ

  • ±â¾÷ °³¿ä
    • Merck KGaA
    • Sanofi
    • AlpalifeB Inc
    • GenScript
    • Novartis International AG
    • Taisho Pharmaceutical Holdings Co., Ltd.
    • Sino Biological, Inc.
    • GeneMedi
    • Biocytogen
    • Abnova Corporation
    • NanoTag Biotechnologies
    • Avillion LLP
    • Capra Science
    • Numab Therapeutics
    • CUSABIO TECHNOLOGY LLC
    • Proteintech Group, Inc.
    • GT Biopharma, Inc.
    • Confo Therapeutics
    • R&D Systems, Inc.
    • Abcepta Biotech Ltd. Co.
  • ¾Ö³Î¸®½ºÆ®ÀÇ °ßÇØ

Á¦11Àå ¼½¼Ç

  • Âü°í ¹®Çå
  • Á¶»ç ¹æ¹ý
KSA 23.10.26

The global nanobodies market is estimated to be valued at US$ 368.6 million in 2023 and is expected to exhibit a CAGR of 24.1% during the forecast period (2023-2030).

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 368.6 Mn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 24.10% 2030 Value Projection: US$ 1,671.9 Mn
Global Nanobodies Market Share (%), By Product Type, 2023
Nanobodies Market - IMG1

Single-domain antibodies known as "nanobodies" are derived from heavy-chain antibodies in mammals and have special characteristics such as nanoscale size, robust structure, stable and soluble behaviours in aqueous solution, reversible protein folding, high affinity and specificity for only one cognate target, among others. Nanobodies have a variety of applications, ranging from basic science to clinical therapeutics. Due to the small size and single-domain chain, nanobodies have a larger binding surface and lower nonspecific background binding and are used as affinity capture reagents. Furthermore, nanobodies can be used to treat cancer and other diseases by blocking ligand-receptor interactions, such as antagonizing the anti-von Willebrand factor to prevent thrombosis or inhibiting anti-TNF-¥á to treat arthritis. Nanobodies can also be expressed inside cells and fused with a fluorescent protein to monitor antigen activity. Nanobodies are well suited as protein stabilizers, which is particularly important during the crystallization of a protein. Thus, nanobodies are used in a number of protein crystallization studies due to the ability of nanobodies to lock proteins in a particular conformation stabilize flexible domains. This, increases the adoption of nanobodies and, thereby, drives the growth of the nanobodies market.

Market Dynamics

The key players in the nanobodies market are focusing on the development of new products by investing in research and development to strengthen their product portfolio. Thus, the introduction of such advanced products in the market is expected to drive growth of the global nanobodies market over the forecast period. For instance, in October 2020, Merck KGaA, a global science and technology company, entered into an out-licensing agreement with Novartis AG, a global healthcare company, for the development of M6495, an anti-ADAMTS5 nanobody, for the potential treatment of osteoarthritis (OA). This increased treatment option for osteoarthritis patients.

Key features of the study:

  • The report provides an in-depth analysis of the global nanobodies market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for the market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global nanobodies market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of thestudy include Merck KGaA, Sanofi, AlpalifeB Inc, GenScript, Novartis International AG, Taisho Pharmaceutical Holdings Co., Ltd., Sino Biological, Inc., GeneMedi, Biocytogen, Abnova Corporation, NanoTag Biotechnologies, Avillion LLP, Capra Science, Numab Therapeutics, CUSABIO TECHNOLOGY LLC, Proteintech Group, Inc., GT Biopharma, Inc., Confo Therapeutics, R&D Systems, Inc., Abcepta Biotech Ltd. Co.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global nanobodies market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nanobodies market

Detailed Segmentation:

  • Global Nanobodies Market, By Product Type:
    • Monovalent Nanobodies
    • Bivalent Nanobodies
    • Bispecific Nanobodies
    • Biparatopic Nanobodies
    • Multivalent Nanobodies
    • Fusion Nanobodies
  • Global Nanobodies Market, By Therapeutic Area:
    • Oncology
    • Infectious Diseases
    • Inflammatory and Autoimmune Diseases
    • Neurological Disorders
    • Others
  • Global Nanobodies Market, By Application:
    • Therapeutic
    • Diagnostic
    • Research
  • Global Nanobodies Market, By End User:
    • Hospitals
    • Biopharmaceutical Companies
    • Diagnostic Laboratories
    • Others
  • Global Nanobodies Market, By Region:
    • North America
    • Europe
    • Asia-Pacific
    • Latin America
    • Middle East & Africa
  • Company Profiles
    • Merck KGaA
    • Sanofi
    • AlpalifeB Inc
    • GenScript
    • Novartis International AG
    • Taisho Pharmaceutical Holdings Co., Ltd.
    • Sino Biological, Inc.
    • GeneMedi
    • Biocytogen
    • Abnova Corporation
    • NanoTag Biotechnologies
    • Avillion LLP
    • Capra Science
    • Numab Therapeutics
    • CUSABIO TECHNOLOGY LLC
    • Proteintech Group, Inc.
    • GT Biopharma, Inc.
    • Confo Therapeutics
    • R&D Systems, Inc.
    • Abcepta Biotech Ltd. Co.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Product Type
    • Market Snippet, By Therapeutic Area
    • Market Snippet, By Application
    • Market Snippet, By End User
    • Market Snippet, By Region
    • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

    • Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
    • Recent Trends
    • Merger, Acquisition, and Collaborations
    • Regulatory Scenario
    • Key Developments
    • PEST Analysis
    • PORTER's Analysis

4. Global Nanobodies Market - COVID-19 Impact Analysis

    • Economic Impact
    • COVID-19 Epidemiology
    • Impact on Supply and Demand

5. Global Nanobodies Market, By Product Type, 2018- 2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Monovalent Nanobodies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends
  • Bivalent Nanobodies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends
  • Bispecific Nanobodies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends
  • Biparatopic Nanobodies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends
  • Multivalent Nanobodies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends
  • Fusion Nanobodies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends

6. Global Nanobodies Market, By Therapeutic Area, 2018 - 2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Oncology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends
  • Infectious Diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends
  • Inflammatory and Autoimmune Diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends
  • Neurological Disorders
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends

7. Global Nanobodies Market, By Application, 2018 - 2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Therapeutic
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends
  • Diagnostic
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends
  • Research
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends

8. Global Nanobodies Market, By End User, 2018 - 2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Biopharmaceutical Companies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Diagnostic Laboratories
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends

9. Global Nanobodies Market, By Region, 2018 - 2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • North America
    • Market Size and Forecast,Y-o-Y Growth, By Product Type, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth, By Therapeutic Area, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth, By Application, 2018-2030, (US$ Mn)
    • Market Size and Forecast,Y-o-Y Growth, By End User, 2018-2030, (US$ Mn)
    • Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
  • U.S.
  • Canada
  • Europe
    • Market Size and Forecast,Y-o-Y Growth, By Product Type, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth, By Therapeutic Area, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth, By Application, 2018-2030, (US$ Mn)
    • Market Size and Forecast,Y-o-Y Growth, By End User, 2018-2030, (US$ Mn)
    • Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast,Y-o-Y Growth, By Product Type, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth, By Therapeutic Area, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth, By Application, 2018-2030, (US$ Mn)
    • Market Size and Forecast,Y-o-Y Growth, By End User, 2018-2030, (US$ Mn)
    • Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast,Y-o-Y Growth, By Product Type, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth, By Therapeutic Area, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth, By Application, 2018-2030, (US$ Mn)
    • Market Size and Forecast,Y-o-Y Growth, By End User, 2018-2030, (US$ Mn)
    • Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
    • Market Size and Forecast,Y-o-Y Growth, By Product Type, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth, By Therapeutic Area, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth, By Application, 2018-2030, (US$ Mn)
    • Market Size and Forecast,Y-o-Y Growth, By End User, 2018-2030, (US$ Mn)
    • Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Market Size and Forecast,Y-o-Y Growth, By Product Type, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth, By Therapeutic Area, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth, By Application, 2018-2030, (US$ Mn)
    • Market Size and Forecast,Y-o-Y Growth, By End User, 2018-2030, (US$ Mn)
    • Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
  • North Africa
  • Central Africa
  • South Africa

10. Competitive Landscape

  • Company Profiles
    • Merck KGaA
    • Sanofi
    • AlpalifeB Inc
    • GenScript
    • Novartis International AG
    • Taisho Pharmaceutical Holdings Co., Ltd.
    • Sino Biological, Inc.
    • GeneMedi
    • Biocytogen
    • Abnova Corporation
    • NanoTag Biotechnologies
    • Avillion LLP
    • Capra Science
    • Numab Therapeutics
    • CUSABIO TECHNOLOGY LLC
    • Proteintech Group, Inc.
    • GT Biopharma, Inc.
    • Confo Therapeutics
    • R&D Systems, Inc.
    • Abcepta Biotech Ltd. Co.
  • Analysts' Views

11. Section

  • References
  • Research Methodology
  • About us and Sales Contact
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦